AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25023807 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% WDGS
Number of subjects: 24
Study 25023807 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% WDGS
Number of subjects: 24
Study 25023807 — intervention group
Group type: COMPARATOR
Intervention: 0% WDGS (Control)
Number of subjects: 24
Study 25023807 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% WDGS vs 60% WDGS
Number of subjects: 24
Study 22309355 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose of 12 mg/kg body-weight (group B)
Number of subjects: 23
Study 22309355 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin loading dose of 6 mg/kg body-weight (group A)
Number of subjects: 23
Study 20649710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg, single dose)
Number of subjects: 0
Study 20649710 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (twice daily)
Number of subjects: 0
Study 18724234 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (tacrolimus withdrawal)
Number of subjects: 87
Study 18724234 — intervention group
Group type: COMPARATOR
Intervention: Group I (control)
Number of subjects: 87
Study 15668287 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 30 mg/m(2) and irinotecan 60 mg/m(2) (days 1 and 8)
Number of subjects: 130
Study 15668287 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 75 mg/m(2) (day 1)
Number of subjects: 130
Study 15668287 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination arm (docetaxel + irinotecan)
Number of subjects: 130
Study 15668287 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel arm
Number of subjects: 130
Study 12566596 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 10708286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 112
Study 10708286 — intervention group
Group type: COMPARATOR
Intervention: Indinavir
Number of subjects: 112
Study 9205415 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial arterial recording force at 2, 5 and 10-100% (10% increments) of the brachial arterial force
Number of subjects: 10
Study 7901680 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (mean concentration 0.35 microgram/g in cases)
Number of subjects: 1410
Study 7901680 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (in smokers)
Number of subjects: 1410
Study 7901680 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (mean concentration 193 micrograms/g in cases)
Number of subjects: 1410
Study 7901680 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean beta-carotene concentration 0.42 microgram/g)
Number of subjects: 1410
Study 2877593 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.015 + 0.085 mg/kg body weight at a 3 min interval
Number of subjects: 0
Study 2877593 — intervention group
Group type: COMPARATOR
Intervention: Single dose of vecuronium 0.1 mg/kg body weight
Number of subjects: 0
Study 29340745 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week warm-up-based ACL injury prevention programme
Number of subjects: 97
Study 29340745 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 27636144 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus palonosetron (0.075 mg)
Number of subjects: 88
Study 27636144 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant plus ramosetron (0.3 mg)
Number of subjects: 88
Study 24698672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg, twice a day)
Number of subjects: 189
Study 24698672 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 189
Study 23955431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine at 10 (11) vp/mL
Number of subjects: 72
Study 23955431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine at 10 (10) vp/mL
Number of subjects: 72
Study 23955431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine at 10 (10) vp/mL and 10 (11) vp/mL
Number of subjects: 72
Study 23955431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine (all doses)
Number of subjects: 72
Study 23955431 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 72
Study 20846292 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH-stimulated 21-deoxycortisol (21DF)
Number of subjects: 106
Study 20846292 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone (17OHP)
Number of subjects: 106
Study 20846292 — intervention group
Group type: EXPERIMENTAL
Intervention: Quotient [(21DF + 17OHP)/F]
Number of subjects: 106
Study 20846292 — intervention group
Group type: COMPARATOR
Intervention: ACTH-stimulated 21DF
Number of subjects: 106
Study 20846292 — intervention group
Group type: COMPARATOR
Intervention: 17OHP
Number of subjects: 106
Study 20846292 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between 21DF and 17OHP
Number of subjects: 106
Study 19186342 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcinia mangostana L. pericarp gel (GM gel) applied topically as an adjunct to periodontal treatment
Number of subjects: 0
Study 19186342 — intervention group
Group type: COMPARATOR
Intervention: Control group (scaling and root planing without GM gel application)
Number of subjects: 0
Study 19186342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 0
Study 16634974 — intervention group
Group type: EXPERIMENTAL
Intervention: High quality day care provided by the Early Years Centre
Number of subjects: 0
Study 16634974 — intervention group
Group type: COMPARATOR
Intervention: Other child care secured by participants
Number of subjects: 0
Study 12870680 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT)
Number of subjects: 0
Study 12870680 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11077934 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial IL6 level in infants with possible infection
Number of subjects: 255
Study 11077934 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial IL6 level in infants with probable infection
Number of subjects: 255
Study 11077934 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial IL6 level in infants with definite infection
Number of subjects: 255
Study 11077934 — intervention group
Group type: COMPARATOR
Intervention: Initial IL6 level in infants without infection
Number of subjects: 255
Study 8839551 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist triptorelin (3.75 mg monthly injections)
Number of subjects: 135
Study 8839551 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 135
Study 30200281 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A therapy (BoNT‐A) combined with intensive rehabilitation (IR)
Number of subjects: 35
Study 26702123 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (PY)
Number of subjects: 89
Study 26702123 — intervention group
Group type: COMPARATOR
Intervention: Low-fat yogurt (LF)
Number of subjects: 89
Study 24243216 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed reformulated OxyContin® (ORF) 30mg
Number of subjects: 27
Study 24243216 — intervention group
Group type: COMPARATOR
Intervention: Crushed original OxyContin® (OC) 30mg
Number of subjects: 27
Study 24243216 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone powder (Oxy API) 30mg
Number of subjects: 27
Study 24243216 — intervention group
Group type: COMPARATOR
Intervention: OC placebo
Number of subjects: 27
Study 23751252 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous ready-to-use therapeutic food (RUTF) in outpatient therapeutic program (OTP)
Number of subjects: 26
Study 23751252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RUTF)
Number of subjects: 26
Study 19394603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative multimodal analgesia (Diclofenac sodium 100 mg suppository and 0.75% Ropivacaine)
Number of subjects: 66
Study 19394603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 17825128 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly bisphosphonate therapy
Number of subjects: 0
Study 17825128 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly bisphosphonate therapy
Number of subjects: 0
Study 16198878 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.6 mg)
Number of subjects: 29
Study 16198878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ep/LVIPVpw
Number of subjects: 29
Study 16198878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ep/LVIPVpw > 0.74
Number of subjects: 29
Study 12115982 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggering potential from an abnormal end‐plate
Number of subjects: 0
Study 12115982 — intervention group
Group type: COMPARATOR
Intervention: Triggering potential not from an abnormal end‐plate
Number of subjects: 0
Study 9952362 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine combined with HIV hyperimmune immunoglobulin (HIVIG) infusions administered monthly during pregnancy and to the neonate at birth
Number of subjects: 0
Study 9952362 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and intravenous immunoglobulin (IVIG) without HIV antibody
Number of subjects: 0
Study 7484310 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from an ex-smoker who attended the group program
Number of subjects: 3923
Study 7484310 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from a smoker
Number of subjects: 3923
Study 2407030 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine (mean daily dose, 52 mg in 2 divided doses)
Number of subjects: 52
Study 2407030 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (mean daily dose, 155 mg in 2 divided doses)
Number of subjects: 52
Study 2407030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 52
Study 2407030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 6110308 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline (Bricanyl)
Number of subjects: 29
Study 6110308 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131
Number of subjects: 29
Study 6110308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31810058 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal vertical jump on one leg 3 times with arms folded across the chest prefatigue to postfatigue
Number of subjects: 30
Study 31810058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue protocol: standing heel raises on a custom‐built platform until task failure
Number of subjects: 30
Study 31365398 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrief interview with a patient-caregiver followed by a written reflection.
Number of subjects: 189
Study 31365398 — intervention group
Group type: COMPARATOR
Intervention: Written reflection on a memorable patient encounter (Control).
Number of subjects: 189
Study 24923259 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT (Acceptance and Commitment Therapy)
Number of subjects: 238
Study 24117556 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty-guided training (FG)
Number of subjects: 72
Study 24117556 — intervention group
Group type: COMPARATOR
Intervention: Self-guided training (SG)
Number of subjects: 72
Study 20855672 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed 1064-nm Nd:YAG laser treatment
Number of subjects: 19
Study 20017331 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ capsule 150 mg/m2 orally on days 1-5 and CCNU placebo 130 mg/m2 on day 1
Number of subjects: 97
Study 20017331 — intervention group
Group type: COMPARATOR
Intervention: CCNU capsule 130 mg/m2 orally on day 1 and TMZ placebo 150 mg/m2 on days 1-5
Number of subjects: 97
Study 16696391 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative '3-in-1' Femoral Nerve Block (FNB) using 30 mL of bupivacaine 0.25%
Number of subjects: 48
Study 16696391 — intervention group
Group type: COMPARATOR
Intervention: Postoperative '3-in-1' Femoral Nerve Block (FNB) using 30 mL of bupivacaine 0.25%
Number of subjects: 48
Study 15477703 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized visual feedback-based balance training
Number of subjects: 27
Study 15477703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 11399957 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV/SQV/d4T
Number of subjects: 175
Study 11399957 — intervention group
Group type: COMPARATOR
Intervention: RTV/SQV
Number of subjects: 175
Study 9244033 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70
Study 9244033 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 70
Study 8101048 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 26
Study 3436330 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (1.5 ml kg‐1)
Number of subjects: 20
Study 3436330 — intervention group
Group type: EXPERIMENTAL
Intervention: Amidotrizoate (1.5 ml kg‐1)
Number of subjects: 20
Study 3436330 — intervention group
Group type: COMPARATOR
Intervention: Amidotrizoate (40 ml)
Number of subjects: 20
Study 3436330 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (40 ml)
Number of subjects: 20
Study 28721947 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-scatter grid (current departmental protocol)
Number of subjects: 70
Study 28721947 — intervention group
Group type: EXPERIMENTAL
Intervention: No anti-scatter grid
Number of subjects: 70
Study 28721947 — intervention group
Group type: EXPERIMENTAL
Intervention: No anti-scatter grid with a 15 cm air-gap
Number of subjects: 70
Study 26126162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (4-mm cap)
Number of subjects: 1113
Study 26126162 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 1113
Study 23228561 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate sodium (35 mg/wk) for 4 months
Number of subjects: 20
Study 23228561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21907152 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditators
Number of subjects: 16
Study 21907152 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 21907152 — intervention group
Group type: COMPARATOR
Intervention: Comparison between meditators and controls
Number of subjects: 16
Study 18088197 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16-24 mg/day)
Number of subjects: 0
Study 18088197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15942543 — intervention group
Group type: EXPERIMENTAL
Intervention: Health at every size group
Number of subjects: 78
Study 15942543 — intervention group
Group type: COMPARATOR
Intervention: Diet group
Number of subjects: 78
Study 12585724 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnosine (800 mg daily for 8 weeks)
Number of subjects: 31
Study 12585724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10214738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 11
Study 7737260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol (12.5, 25, and 50 micrograms kg‐1 h‐1)
Number of subjects: 8
Study 7737260 — intervention group
Group type: COMPARATOR
Intervention: Atropine (5 micrograms kg‐1 h‐1)
Number of subjects: 8
Study 7737260 — intervention group
Group type: COMPARATOR
Intervention: Loxiglumide (10 mg kg‐1 h‐1)
Number of subjects: 8
Study 2048810 — intervention group
Group type: EXPERIMENTAL
Intervention: APRV
Number of subjects: 9
Study 2048810 — intervention group
Group type: COMPARATOR
Intervention: SIMV
Number of subjects: 9
Study 7093133 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (Tice strain)
Number of subjects: 78
Study 7093133 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 31306076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) treatment
Number of subjects: 38
Study 31306076 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (sham appliance)
Number of subjects: 38
Study 30552531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery Enhancement Therapy
Number of subjects: 134
Study 30552531 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 134
Study 30378151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (GTN)
Number of subjects: 43
Study 30378151 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (n=13)
Number of subjects: 43
Study 30378151 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (n=14)
Number of subjects: 43
Study 30378151 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (n=16)
Number of subjects: 43
Study 28767584 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-emotive health education intervention (REHEI)
Number of subjects: 0
Study 28767584 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 25932544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 100
Study 25932544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 800 mg/day
Number of subjects: 100
Study 25932544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25932544 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg/day
Number of subjects: 100
Study 23153560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (300mg/d) alone for 7 days
Number of subjects: 24
Study 23153560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (300mg/d) with SFN (450μmol)
Number of subjects: 24
Study 23153560 — intervention group
Group type: EXPERIMENTAL
Intervention: SFN (450μmol) alone
Number of subjects: 24
Study 21598023 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based behavioral interventions
Number of subjects: 452
Study 19506391 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1.3, 2.0, and 2.7 mg/m²/day)
Number of subjects: 39
Study 19506391 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 39
Study 16522903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-inspired diet (MID)
Number of subjects: 22
Study 16522903 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Swedish diet (OSD)
Number of subjects: 22
Study 15449633 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat wrap therapy
Number of subjects: 371
Study 15449633 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 371
Study 15449633 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 371
Study 11269569 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 10 hours
Number of subjects: 16
Study 11269569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion 1 hour before breakfast
Number of subjects: 16
Study 11269569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion immediately following consumption of the breakfast
Number of subjects: 16
Study 11269569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion 1.5 hours after beginning consumption of the breakfast
Number of subjects: 16
Study 11269569 — intervention group
Group type: COMPARATOR
Intervention: Ingestion immediately after meal vs 1.5 hours postmeal
Number of subjects: 16
Study 9408426 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated 7-FR femoral venous catheters
Number of subjects: 42
Study 9408426 — intervention group
Group type: COMPARATOR
Intervention: Control legs (contralateral leg without catheter)
Number of subjects: 42
Study 8208641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10‐40 mg once daily
Number of subjects: 127
Study 8208641 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20‐40 mg twice daily
Number of subjects: 127
Study 3114434 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP-5 (doxorubicin and a five‐day course of cisplatin alternating with cyclophosphamide and hexamethylmelamine orally for 14 days)
Number of subjects: 191
Study 3114434 — intervention group
Group type: COMPARATOR
Intervention: CP (cyclophosphamide and cisplatin both administered intravenously on a single day at 3‐week intervals)
Number of subjects: 191
Study 29121334 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg dronabinol
Number of subjects: 73
Study 29121334 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dronabinol
Number of subjects: 73
Study 29121334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 27005755 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training for EVAR
Number of subjects: 18
Study 27005755 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrarenal device
Number of subjects: 18
Study 27005755 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprarenal device
Number of subjects: 18
Study 27005755 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprarenal fixation
Number of subjects: 18
Study 27005755 — intervention group
Group type: COMPARATOR
Intervention: Femoral access side
Number of subjects: 18
Study 24934484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (up to 200 mg/day)
Number of subjects: 50
Study 24934484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24131885 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise session (EX)
Number of subjects: 10
Study 24131885 — intervention group
Group type: COMPARATOR
Intervention: Control session (CON)
Number of subjects: 10
Study 24131885 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest session (BR)
Number of subjects: 10
Study 20578138 — intervention group
Group type: EXPERIMENTAL
Intervention: Band ligation plus nadolol (Combined group)
Number of subjects: 140
Study 20578138 — intervention group
Group type: COMPARATOR
Intervention: Nadolol alone (Nadolol group)
Number of subjects: 140
Study 20578138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 19105351 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine treatment for flat warts, 5 g pre-pack, treated for 30 days.
Number of subjects: 0